HLB BioStep Co

HLB BioStep Co AAQS

The AAQS of HLB BioStep Co (278650.KQ) as of Oct 22, 2026.

AAQS

0

Last updated:

HLB BioStep Co has a current AAQS of 0.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock HLB BioStep Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The HLB BioStep Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.00 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
0.00 KRW
Jan 1, 2025
0.00 KRW
The HLB BioStep Co AAQS history
YEARAAQSYoY
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

On Eulerpool you can find the complete historical development of The AAQS HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — HLB BioStep Co

All Key Metrics — HLB BioStep Co